NCT04103034 - A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

September 14, 2020

Study Completion Date

September 14, 2020

Conditions

Cerebrovascular StrokeLarge-Artery Atherosclerosis (Embolus/Thrombosis)Intracranial Arteriosclerosis

Interventions

DRUG

BT200

BT200 is a PEGylated synthetic RNA oligonucleotide

DRUG

Desmopressin

Sterile solution for injection

DRUG

Placebo

Sterile saline for injection

Trial Locations (1)

Medical University of Vienna, Vienna